ライフサイエンスコーパス: enolase

1 sminogen activators (cytokeratin 8 and alpha-enolase).

2 in serum S100beta, GFAP, and neuron specific enolase.

3 evoked potentials, and serum neuron-specific enolase.

4 it the oxidation of actin and UNP similar to enolase.

5 ation of microRNA levels and neuron-specific enolase.

6 hey did not compete for the interaction with enolase.

7 issue that did not stain for neuron-specific enolase.

8 he mouse model of BA was identified as alpha-enolase.

9 four were identified by mass spectrometry as enolase.

10 regions of sequence homology between RRV and enolase.

11 caspase-11 and the caspase-1 substrate alpha-enolase.

12 id, functions as a potent inhibitor of human enolase.

13 nts: RNase E, PNPase, RhlB RNA helicase, and enolase.

14 carbonyls; in both, lower glycolytic enzyme enolase.

15 l as the binding mode of BV to P. falciparum enolase.

16 The glycolytic gene enolase 1 (ENO1) in the 1p36 locus is deleted in gliobla

17 o 3 proteins identified in previous studies: enolase 1 (ENO1), NK-tumor recognition protein (NKTR), a

18 hydrogenase, triose phosphate isomerase, and enolase 1, are targeted using RNAi in Ras-transformed NI

19 es, including enzymes sponsoring glycolysis (enolase 1, triosephosphate isomerase 1, and hexokinase 2

20 Cell surface-associated enolase-1 (ENO-1) enhances plasmin formation and thus pa

21 ning the functional effects of arrestin-1 on enolase-1 activity in photoreceptors and their surroundi

22 restin-1 can completely remove its effect on enolase-1 activity while still remaining bound to enolas

23 e observed that arrestin-1 primarily engages enolase-1 along a surface that is opposite of the side o

24 he likely source of arrestin's modulation of enolase-1 catalysis, showing that selective substitution

25 eveloped a molecular model of the arrestin-1-enolase-1 complex, which was validated by targeted subst

26 between glycolysis and Foxp3-E2 variants via enolase-1 shows a previously unknown mechanism for contr

27 in-1 binding partners, the glycolysis enzyme enolase-1, to map the molecular contact sites between th

28 arrestin-1 affects the catalytic activity of enolase-1.

29 n 2 (Foxp3-E2) through the glycolytic enzyme enolase-1.

30 se-1 activity while still remaining bound to enolase-1.

31 a total of 299 proteins, we identified alpha-enolase, 14-3-3 protein zeta/delta, cofilin-1, and heat

32 The implementation of alpha-enolase, 14-3-3 protein zeta/delta, cofilin-1, and heat

33 pathway, leading to ERK phosphorylation and enolase 2 (ENO2) expression.

34 d in glycolysis (lactate dehydrogenase A and enolase 2), oxidant stress (FOXO3a), angiogenesis (VEGF)

35 ent selection (isocitrate dehydrogenase 1/2, Enolase 2).

36 green fluorescent protein gene downstream of enolase (23%).

37 (29 kDa), 50% for aldolase (39 kDa), 46% for enolase (46 kDa), and 27% for glutamate dehydrogenase (5

38 e (9 of 12 mice), citrullinated P gingivalis enolase (6 of 6 mice), and uncitrullinated P gingivalis

39 of 6 mice), and uncitrullinated P gingivalis enolase (6 of 6 mice).

40 sitive for antibody (Ab) reactivity to gamma-enolase (8%); alpha-enolase (9%); heat-shock protein 90

41 (9 of 12 mice), uncitrullinated human alpha-enolase (9 of 12 mice), citrullinated P gingivalis enola

42 ice immunized with citrullinated human alpha-enolase (9 of 12 mice), uncitrullinated human alpha-enol

43 (Ab) reactivity to gamma-enolase (8%); alpha-enolase (9%); heat-shock protein 90 (13%); osteopontin (

44 membrane vesicles of B. burgdorferi contain enolase, a glycolytic-cycle enzyme that catalyzes 2-phos

45 dentified the pneumococcal glycolytic enzyme enolase, a nonclassical cell surface and plasminogen-bin

46 diate AMD, and 46% of those with GA had anti-enolase AAbs, compared with 29% of individuals with NV a

47 Enolase activity was also assessed in the presence of ar

48 s truncated form of LOS2 has little, if any, enolase activity, indicating that an intact N-terminal r

49 for quantification was conducted with yeast enolase added to serum as an internal standard.

50 ehyde-3-phosphate dehydrogenase (GAPDH), and enolase, all of which are responsible for energy metabol

51 ermore, in the presence of exogenously added enolase, an increased C4BP binding to and subsequently d

52 ObcA catalyzes its reaction by combining the enolase and acetyltransferase superfamilies, but the pre

53 was evaluated using tryptic digests of yeast enolase and alcohol dehydrogenase.

54 an unexpected role for the metabolic enzymes enolase and aldo-keto reductase as positive and negative

55 In cooked or roasted foods, enolase and aldolase were detectable in chicken breast w

56 LN, where IgG2 autoantibodies against alpha-enolase and annexin AI predominate in the glomerulus and

57 Notably, IgG2 autoantibodies against alpha-enolase and annexin AI were detected in 11 and 10 of the

58 utoantibodies detected, including anti-alpha-enolase and antiannexin AI, identified LN versus SLE and

59 Serum IgG reactivity with alpha-enolase and citrullinated alpha-enolase was assayed by W

60 gher level of tumor markers (neuron-specific enolase and cytokeratin fragment 21-1).

61 e IgG2 recognized specific epitopes of alpha-enolase and did not cross-react with dsDNA.

62 peaked earliest, followed by neuron-specific enolase and finally myelin basic protein.

63 s (aldolase, phosphoglycerate mutase 2, beta enolase and glycogen phosphorylase), transport proteins

64 mechanism of SF2312 inhibition of bacterial enolase and its role in bacterial growth and reproductio

65 e, glycerol-3-phosphate-dehydrogenase, alpha enolase and L-lactate dehydrogenase B-chain) and in oxid

66 Recombinant human alpha-enolase and P gingivalis enolase, either citrullinated o

67 nally we identified two TMs (neuron-specific enolase and pro-gastrin-releasing peptide) that differen

68 d anti-enolase antibodies cross-reacted with enolase and RRV proteins; we identified regions of seque

69 Neuron-specific enolase and S-100 levels increased in the ensuing 4 hrs

70 Serum neuron-specific enolase and S100b concentrations were increased in the u

71 erized biomarkers, including neuron-specific enolase and S100B protein.

72 terized as a mimotope of an ookinete surface enolase and SM1 presumably competes with enolase, the pr

73 s has been identified as citrullinated alpha-enolase and the importance of genetic factors in anticit

74 ere noted in organs from mice immunized with enolase and then challenged with WT bacteria compared to

75 e form, pyruvate kinase muscle isozyme, beta-enolase and triosephosphate isomerase and phosphoglucomu

76 from acidic residues (DNA topoisomerase II, enolase, and C-Raf) show that the relevant acidic residu

77 rogastrin-releasing peptide, neuron-specific enolase, and chromogranin-A) were analyzed in 50 patient

78 in complex ions (e.g., superoxide dismutase, enolase, and hemoglobin) desorbed from solution by liqui

79 erized by the presence of flotillin-1, alpha-enolase, and Hsp70, the same proteins that associate wit

80 Enrollment leptin, neuron-specific enolase, and intracellular cell adhesion molecule-1 leve

81 ne levels of chromogranin A, neuron-specific enolase, and multiple soluble angiogenic biomarkers were

82 data show that serum S100b, neuron-specific enolase, and myelin basic protein may aid in outcome cla

83 (matrix metallopeptidase-9, neuron-specific enolase, and vascular cellular adhesion molecule-1) and

84 ctive allergens involved being parvalbumins, enolases, and aldolases.

85 Plg-Rs include histone 2B, alpha-enolase, annexin 2, and p11, all proteins which lack sig

86 bodies against podocyte antigens (anti-alpha-enolase/antiannexin AI) were also investigated.

87 Anti-RRV and anti-enolase antibodies cross-reacted with enolase and RRV pr

88 The cross-reactivity between an anti-enolase antibody and RRV proteins indicates that molecul

89 e glycolytic enzymes phosphofructokinase and enolase are presented and discussed in relation to their

90 rted biomarkers of acute IS (neuron-specific enolase: area under the curve=0.69; interleukin 6: area

91 ionships for these phosphonates and validate enolase as a promising target for antibiotic discovery.

92 nd plasminogen bound to different domains of enolase as they did not compete for the interaction with

93 rasites identified P. falciparum enolase (Pf enolase) as the strongest candidate.

94 e Mp65 adhesin and a "moonlighting" protein, enolase, as partners for the interaction with P. gingiva

95 y measure injury to neurons (neuron-specific enolase), astrocytes (S100b), and axons (myelin basic pr

96 alpha-Enolase autoantibody specificity was confirmed by ELISA

97 Additionally, S100 protein, neuron-specific enolase, beta-amyloid protein, tau protein and phospho-t

98 th SM1 and ookinete surface enolase, termed "enolase-binding protein" (EBP).

99 The enolase binds plasminogen in a lysine-dependent manner b

100 Antibodies to human alpha-enolase, both citrullinated and unmodified, and to CEP-1

101 Recombinant enolase bound in a dose-dependent manner C4BP purified f

102 , we detail a structural analysis of E. coli enolase bound to both SF2312 and its oxidized imide-form

103 Under anaerobic conditions, enolase bound to the RNase E/degradosome stabilizes the

104 We provide a mechanism by which Ecoli uses enolase-bound degradosomes to switch from rod-shaped to

105 to collagen, tropomyosin, aldolase A or beta-enolase but not parvalbumin.

106 tein substrates, such as alpha-synuclein and enolase, but also activated proteasome in cultured fibro

107 Citrullination of human fibrinogen and alpha-enolase by P gingivalis was studied by incubating live w

108 Importantly, we demonstrate that surface enolase captures plasminogen from the mammalian blood me

109 d-type P gingivalis with fibrinogen or alpha-enolase caused degradation of the proteins and citrullin

110 tibodies to peptide 1 of citrullinated alpha-enolase (CEP-1) and its arginine-bearing control peptide

111 As compared to neuron-specific enolase, circulating microRNAs are modest but significan

112 Myosin, beta-enolase, CK-M-type and actin were identified as main pro

113 Taken together, the CvfA-enolase complex in S. pyogenes is involved in the regula

114 lcium-binding protein B, and neuron-specific enolase concentrations in plasma and serum were measured

115 Serum S100 beta (S100B) and neuron-specific enolase concentrations rise after brain injury.

116 es to interfere with the function of surface enolase could contribute to the development of novel pre

117 the geometric area under the neuron-specific enolase curve from 24 to 72 hours after admission.

118 rences in the area under the neuron-specific enolase curve, or a composite end point of death and poo

119 ssed spots were found and identified, namely enolase, cyclophilin-A, ribosomal protein L13 and actin-

120 nctionalized sol-gels was performed using an enolase digested peptide mixture, a beta-casein digested

121 As expected, enolase displayed consistent expression in vivo, however

122 RNase E/enolase distribution changes from membrane-associated pa

123 scopy and proteinase K treatment showed that enolase does not appear to be exposed on the surface.

124 mbinant human alpha-enolase and P gingivalis enolase, either citrullinated or uncitrullinated, were u

125 B. burgdorferi enolase, either in a recombinant form or as a membrane-b

126 Confounders of neuron-specific enolase elevation should be actively considered: neuron-

127 gory 1-2 had confounders for neuron-specific enolase elevation.

128 of lactate dehydrogenase (LDH1 and LDH2) and enolase (ENO1 and ENO2) that are expressed in a stage-sp

129 corresponded to the glycolytic enzymes alpha-enolase (ENO1) and pyruvate kinase isozyme M2 (PKM2), we

130 In mammalian cells, the alpha-enolase (ENO1) gene encodes both a 48 kDa glycolytic enz

131 M interactions induce metabolic enzyme Alpha-Enolase (ENO1) in both pDCs and MM cells.

132 Antibodies against alpha-enolase (ENO1), a glycolytic enzyme, are detected in mor

133 synaptophysin, chromogranin, neuron specific enolase, epidermal growth factor receptor, HER2, CD5, CD

134 entiation, neuron-specific beta3-tubulin and enolase expression was reduced together with an increase

135 active immunization of mice with recombinant enolase failed to evoke protective immunity against subs

136 I, 2.56-12.16), and elevated neuron-specific enolase (false-positive rate, 0.12; 95% CI, 0.06-0.23; p

137 ceraldehyde-3-phosphate dehydrogenase, alpha-enolase, filamin-A, and heat shock protein 90, were iden

138 de evidence that phosphoglycerate mutase and enolase form a substrate-channelling metabolon which is

139 , we demonstrated that the surface-expressed enolase from diarrheal isolate SSU of Aeromonas hydrophi

140 re detected in the levels of neuron-specific enolase from preseason values (median, 6.5 mug/L; range,

141 asting serum chromogranin A, neuron-specific enolase, gastrin, glucagon, vasoactive intestinal peptid

142 he insertion-deletion (indel) process in the enolase gene across the Tree of Life using the phylogene

143 We also showed that the enolase gene could potentially be important for the viab

144 we could delete the chromosomal copy of the enolase gene only when another copy of the targeted gene

145 nally diverse superfamilies (amidohydrolase, enolase, glutathione transferase, haloalkanoic acid deha

146 4%, respectively), and serum neuron specific enolase greater than 33 ng/mL (23% vs 8%; all p < 0.01):

147 , presence of myoclonus, and neuron-specific enolase greater than 75 microg/L; accuracy was highest f

148 All three patients with neuron-specific enolase greater than 90 mug/L and Cerebral Performance C

149 f good outcome patients with neuron-specific enolase greater than 90 mug/L and poor outcome patients

150 We measured levels of neuronal-specific enolase, growth-associated protein 43, nerve growth fact

151 romogranin A (>/=600 mug/L), neuron-specific enolase (>/=25 mug/L), and classic grading (Ki-67-based)

152 High levels of serum anti-alpha-enolase (>15 mg/L) IgG2 and/or anti-annexin AI (>2.7 mg/

153 specificity, serum S100b and neuron-specific enolase had optimal positive and negative predictive val

154 xin AI IgG2 and patients with low anti-alpha-enolase/high anti-annexin AI IgG2.

155 ormothermia (p = 0.013), and neuron-specific enolase higher than 33 mug/L (p = 0.029), but not somato

156 Anti-H3 and anti-alpha-enolase IgG2 levels had the most remarkable increase in

157 Anti-alpha-enolase IgG2 recognized specific epitopes of alpha-enola

158 atients with BA had increased levels of anti-enolase IgM and IgG.

159 In contrast, enolase immunization of murine hosts significantly reduc

160 of WT bacteria in the livers and spleens of enolase-immunized mice than that found in the nonimmuniz

161 Instead, CvfA interacted with enolase, implying that CvfA, a putative RNase, controls

162 have identified autoantibodies against alpha-enolase in a mouse model of BA (infected with RRV) and i

163 at positions 343, 394, 420, 427, and 430 of enolase in A. hydrophila SSU; the mutated forms of enola

164 Lyme disease patients exhibit recognition of enolase in serologic assays.

165 defined by antibodies to citrullinated alpha-enolase in the context of DR4.

166 However, enolase in the outer membrane vesicles is accessible to

167 the direct involvement of surface-expressed enolase in the pathogenesis of A. hydrophila SSU infecti

168 However, the role of enolase in the RNase E/degradosome is not understood.

169 Here, we report that presence of enolase in the RNase E/degradosome under anaerobic condi

170 rillum rubrum is also able to function as an enolase in vivo as part of an MSP, but only under anaero

171 M. aeruginosa RLPs function as tautomerases/enolases in a methionine salvage pathway (MSP).

172 ) or a target protein (i.e., neuron specific enolase) in buffer.

173 ition of glucose transport, or inhibition of enolase, increased SIRT1 protein levels in normal human

174 tial of ENO1-deleted GBM cells, and that the enolase inhibitor phosphonoacetohydroxamate is selective

175 252)FYDAEKKEY(260)) in the A. hydrophila SSU enolase involved in plasminogen binding.

176 Neuron-specific enolase is an easily available, observer-independent pro

177 eferentially localized in nuclei while alpha-enolase is found in the cytoplasm.

178 lly blocked, while the wild-type chromosomal enolase is secreted normally in the same cultures during

179 the secretion of plasmid gene-encoded mutant enolase is totally blocked, while the wild-type chromoso

180 evoked potentials, and serum neuron-specific enolase, is recommended; however, no study examined the

181 One such difference was the number of enolase isoforms and their sum abundance; castor had app

182 d poor outcome patients with neuron-specific enolase less than or equal to 17 mug/L (upper limit of n

183 majority of 14 patients with neuron-specific enolase less than or equal to 17 mug/L who died had a ca

184 mor burden, and the baseline neuron-specific enolase level.

185 Exenatide did not reduce neuron-specific enolase levels and did not significantly improve a compo

186 at all time points and lower neuron-specific enolase levels on days 1 and 3 compared with those with

187 lysosomal thiol-reductase GILT, and a 47-kDa enolase-like protein.

188 Here, we show that enolase lines the ookinete surface.

189 Enolase localization in photoreceptors was assessed by i

190 d two cohorts: patients with high anti-alpha-enolase/low anti-annexin AI IgG2 and patients with low a

191 ted protein 2), and energy metabolism (alpha-enolase, malate dehydrogenase, triosephosphate isomerase

192 i and Plasmodium falciparum, suggesting that enolase may act as an invasion ligand.

193 n suggests that the unmodified form of alpha-enolase may be important in initiating the corresponding

194 otein, CD11b), and neuronal (neuron-specific enolase, neuronal nitric oxide synthase) markers in IR(A

195 Serum levels of neuron-specific enolase (NSE) and neuron-enriched S100 beta (S100beta) w

196 the molecular recognition of neuron specific enolase (NSE) biomarker.

197 sensitive diagnosis of human neuron-specific enolase (NSE) cancer biomarkers.

198 oembryonic antigen (CEA) and neuron-specific enolase (NSE) in a clinical sample with high sensitivity

199 Neuron-specific enolase (NSE) is a biomarker for neuronal stress.

200 Neuron-specific enolase (NSE) is a widely-used biomarker for prognostica

201 leasing peptide (ProGRP) and neuron specific enolase (NSE) is presented, which involves coextraction

202 Serum neuron specific enolase (NSE) measurements, brain imaging findings, soma

203 d electrochemical sensor for neuron specific enolase (NSE) was developed by electrochemical polymeriz

204 Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if elevated at basel

205 sfully used for detection of neuron-specific enolase (NSE), a traumatic brain injury (TBI) protein bi

206 for the neuromarkers S100B, neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP

207 y of neurologic examination, neuron-specific enolase (NSE), and median nerve somatosensory-evoked pot

208 ysteine modified epitopes of neuron specific enolase (NSE), as-synthesized gold nanoparticles (AuNPs)

209 osensor for the detection of neuron-specific enolase (NSE).

210 ium bromine ionic liquid and neuron specific enolase (NSE).

211 d higher accuracy than serum neuron-specific enolase (NSE; the area under the receiver operating char

212 istamine receptor H1 [HRH1], neuron-specific enolase [NSE] [ENO2], neuronal protein gene product 9.5

213 lactate dehydrogenase and 77 neuron-specific enolase observations), the statistical framework prospec

214 d a baseline plasma level of neuron-specific enolase of greater than 15 ng/mL independently predicted

215 graphy reactivity, and serum neuron-specific enolase offers the best outcome predictive performance f

216 ported cases of plasminogen binding to alpha-enolase on mammalian cells, as well as mechanisms by whi

217 The results support the hypothesis that enolase on the surface of Plasmodium ookinetes plays a d

218 tochemistry revealed colocalization of alpha-enolase or annexin AI with IgG2 in glomeruli.

219 ubsequently characterized by neuron-specific enolase or glial fibrillary acidic protein expression, a

220 hromosomal gene product BB0337, annotated as enolase or phosphopyruvate dehydratase, is associated wi

221 motif) ligand 2 (p = 0.030), neuron-specific enolase (p = 0.006), and S100b (p = 0.015) and in patien

222 is, markedly elevated plasma neuron-specific enolase (P = 0.016; hazard ratio, 2.9; 95% CI, 1.2-7.0)

223 ase activity of GD3- cell-derived Yes toward enolase, p125, and Yes itself.

224 c phosphorylated and un-phosphorylated alpha-enolase peptides with sera of healthy and PDAC patients.

225 ithin the parasites identified P. falciparum enolase (Pf enolase) as the strongest candidate.

226 -PHOSPHATE-ISOMERASE1 (MTI1) and DEHYDRATASE-ENOLASE-PHOSPHATASE-COMPLEX1 (DEP1) under different S co

227 se Y, polynucleotide phosphorylase (PNPase), enolase, phosphofructokinase, and a DEAD box RNA helicas

228 ted baseline chromogranin A, neuron-specific enolase, placental growth factor, and soluble vascular e

229 ide and (EPIP)(4), four copies of Plasmodium enolase-plasminogen interaction peptide that prevents pl

230 lamina propria occupied by neuronal-specific enolase-positive (57.7% increase) and growth-associated

231 ould be actively considered: neuron-specific enolase-producing tumors, acute brain diseases, and hemo

232 ig4 under the control of the neuron-specific enolase promoter and the astrocyte-specific glial fibril

233 gin under the control of the neuron-specific enolase promoter) or fewer than normal (Hand2(+/-) mice)

234 forced expression, via the neuronal specific enolase promoter, showed protection against the learned

235 tured from brain cortices of neuron-specific enolase promoter-driven apoE3 (NSE-apoE3) or apoE4 (NSE-

236 CatB under the control of a neuron-specific enolase promoter.

237 d1) under the control of the neuron-specific enolase promoter.

238 antibodies against carbonic anhydrase II and enolase proteins with a negative genetic retinal dystrop

239 cytoplasmic functions, include GroEL, DnaK, enolase, pyruvate dehydrogenase subunits PdhB and PdhD,

240 increases key glycolytic proteins, including enolase, pyruvate kinase M2 (PKM2), lactate dehydrogenas

241 se, unnamed protein product (UNP) similar to enolase, pyruvate kinase, isoforms of creatine kinase, a

242 - and 4-hr postresuscitation neuron-specific enolase (r = -.86, p < .001 and r = -.87, p < .001, resp

243 that this RuBisCO catalyzes the DK-MTP 1-P "enolase" reaction either in vitro or in vivo.

244 -methylthiopentane 1-phosphate (DK-MTP 1-P) "enolase" reaction in the well-known "methionine salvage"

245 Enolase recruited C4BP and plasminogen, but not factor H

246 ckout mutation of phosphoglycerate mutase or enolase resulted in a significantly reduced association

247 C4BP bound to the enolase retained its cofactor activity as determined by

248 When the enolase-RNase E/degradosome interaction is disrupted, th

249 and biochemical parameters (neuron-specific enolase, S-100).

250 markers include 14-3-3, tau, neuron-specific enolase, S100B, and alpha-synuclein.

251 We measured serum neuron-specific enolase, S100b, and myelin basic protein on days 1-4 and

252 mokine (C-C motif) ligand 2, neuron-specific enolase, S100b, intercellular adhesion molecule-5, and b

253 A neuron-specific enolase serum concentration greater than 90 mug/L predic

254 An neuron-specific enolase serum concentration less than or equal to 17 mug

255 We analyzed neuron-specific enolase serum concentrations 3 days after nontraumatic i

256 Neuron-specific enolase serum concentrations less than or equal to 17 mu

257 High neuron-specific enolase serum concentrations reliably predicted poor out

258 munization of mice with purified recombinant enolase significantly protected the animals against a le

259 correlated with higher serum neuron-specific enolase (Spearman r = -0.52, p < 0.0001).

260 try using recombinant full-length Plasmodium enolase suggested one binding site for BV.

261 rone MRL-lpr/lpr mice recognized human alpha-enolase, suggesting homology between animal models and h

262 amidohydrolase, metallo-beta-lactamase, and enolase superfamilies.

263 ate lactonizing enzyme (MLE) subgroup of the enolase superfamily (UniProt ID A0NXQ8 ).

264 tructure of an uncharacterized member of the enolase superfamily from Oceanobacillus iheyensis (GI 23

265 The mechanistically diverse enolase superfamily is a paradigm for elucidating Nature

266 The mechanistically diverse enolase superfamily is a paradigm for understanding the

267 d investigation of a group of enzymes in the enolase superfamily that are involved in epimerizing dip

268 es for assigning functions to members of the enolase superfamily that should be applicable to other s

269 different homologous progenitors within the enolase superfamily, in which different spatial arrangem

270 The OSBS family belongs to the enolase superfamily, members of which use a set of conse

271 gs to the mandelate racemase subgroup in the enolase superfamily.

272 d structurally characterized subgroup in the enolase superfamily.

273 tor that binds both SM1 and ookinete surface enolase, termed "enolase-binding protein" (EBP).

274 toglobulin), dimeric (beta-lactoglobulin and enolase), tetrameric (streptavidin, concanavalin A, and

275 ed a hydrophobic alpha-helical domain within enolase that contributes to its secretion.

276 ace enolase and SM1 presumably competes with enolase, the presumed ligand, for binding to a putative

277 hat links an immune response to P gingivalis enolase to an important subset of RA, defined by antibod

278 r curves for serum S100b and neuron-specific enolase to classify favorable versus unfavorable outcome

279 he serum biomarkers S100 and neuron-specific enolase to clinical characteristics for predicting outco

280 We propose that BV targets enolase to reduce parasite glycolysis rates and changes

281 2.89 (95% CI, 1.09-7.73) for neuron-specific enolase, using a cutoff of 62.0 ng/mL, and 2.15 (95% CI,

282 Enolase, UTP-glucose-1-phosphate uridylyltransferase and

283 The LOQ with extracted serum samples for enolase was 1 muM, linear from 1 to 40 muM, the highest

284 Neuron-specific enolase was an accurate predictor of neurological outcom

285 y with alpha-enolase and citrullinated alpha-enolase was assayed by Western blotting and enzyme-linke

286 The enolase was cloned, expressed, purified, and used to gen

287 This increased enolase was enzymatically inactive and associated with t

288 xhibits significant similarity to the enzyme enolase was isolated.

289 its classic role in carbohydrate metabolism, enolase was recently found to localize to membranes, whe

290 ition of glucose transport, or inhibition of enolase, was dependent on SIRT1.

291 lysine residues at positions 420 and 427 of enolase were crucial in plasminogen-binding activity.

292 e in A. hydrophila SSU; the mutated forms of enolase were hyperexpressed in Escherichia coli, and the

293 ng individual domains, two binding sites for enolase were identified on the complement control protei

294 potentials (SSEP), and serum neuron-specific enolase were performed in parallel, as part of standard

295 valbumin and two new allergens, aldolase and enolase, were identified at 12, 40, and 50 kDa, respecti

296 mbionts lack the essential glycolytic enzyme enolase, which may be overcome by the exchange of interm

297 cluding ATPase, clathrin, peroxiredoxins and enolase, which may provide clues to the molecular mechan

298 ci specifically interact with human C4BP via enolase, which represents an additional mechanism of hum

299 The LOS2 gene in Arabidopsis encodes an enolase with 72% amino acid sequence identity with human

300 ephalography reactivity, and neuron-specific enolase yielded the best predictive performance (receivi